Aldeyra Therapeutics Receives Second FDA Complete Response Letter for Lead Dry Eye Drug Reproxalap

summarizeSummary

Aldeyra Therapeutics announced receipt of a second Complete Response Letter from the FDA for its lead dry eye drug, reproxalap, citing a lack of substantial efficacy evidence.

check_boxKey Events

• FDA Issues Second Complete Response Letter for Reproxalap

  The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Aldeyra's New Drug Application (NDA) for reproxalap for dry eye disease, marking the second such letter for the drug.

• Efficacy Concerns Cited by FDA

  The CRL stated a 'lack of substantial evidence' and that the application 'failed to demonstrate efficacy in adequate and well controlled studies,' raising 'serious concerns about the reliability and meaningfulness of the positive findings.'

• No Safety or Manufacturing Issues Identified

  Consistent with prior reviews, the FDA did not identify any safety or manufacturing concerns with reproxalap.

• Company Plans Type A Meeting with FDA

  Aldeyra intends to expeditiously request a Type A meeting with the FDA to understand the actions needed for NDA approval, with a target meeting date within 30 days.

auto_awesomeAnalysis

Aldeyra Therapeutics has received a second Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for reproxalap, its lead investigational drug for dry eye disease. The FDA cited a "lack of substantial evidence" and failure to demonstrate efficacy in adequate and well-controlled studies, raising serious concerns about the reliability of positive findings. This follows a previous CRL in April 2025 and multiple PDUFA date extensions, indicating persistent challenges in meeting regulatory efficacy standards. While no safety or manufacturing issues were identified, and the FDA did not explicitly request new trials, the strong language regarding efficacy suggests a significant hurdle for approval. The company's stated cash runway into 2028 provides some financial stability, but the future of its primary asset is now highly uncertain, necessitating a Type A meeting with the FDA to understand the path forward.